FDA approves hydrocortisone oral granules for adrenocortical insufficiency in kids

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2020-10-05 03:30 GMT | Update On 2020-10-05 08:32 GMT

The US Food and Drug Administration (FDA) has approved hydrocortisone (ALKINDI SPRINKLE) oral granules as a replacement therapy for adrenocortical insufficiency (AI) in pediatric patients.

Pediatric adrenocortical Insufficiency (AI) is a rare disease characterized by an inability to synthesize and release cortisol, and sometimes aldosterone. This causes excessive androgens (abnormal sexual development in females, premature puberty, premature growth termination and short stature). To survive, patients with AI must replace the missing cortisol daily

ALKINDI SPRINKLE is an immediate-release oral hydrocortisone granule preparation that has been specifically designed to meet the dosing needs of pediatric patients with adrenocortical insufficiency.

Prior to ALKINDI SPRINKLE's approval, parent caregivers had to cut or split higher strength hydrocortisone tablets to achieve the lower doses required for small children, which could result in inaccurate dosing. ALKINDI SPRINKLE is manufactured using commercially proven technology in four strengths: 0.5mg, 1mg, 2mg and 5mg, to give greater dosing flexibility to clinicians. Taste-masking excipients that are acceptable for pediatric use eliminate the bitter taste of hydrocortisone. ALKINDI SPRINKLE has a shelf life of three years at ambient temperature and does not require refrigeration.

With the approval Eton Pharmaceuticals now has the only FDA-approved granular hydrocortisone formulation for the disease specifically designed for the use in children.

Prior to the approval of ALKINDI SPRINKLE, oral hydrocortisone was only FDA-approved in tablet formulations of 5mg and stronger. Many pediatric patients require significantly lower doses and the flexibility of precision titration. ALKINDI SPRINKLE will now be available in 0.5mg, 1mg, 2mg, and 5mg strengths, allowing clinicians greater flexibility to individualize dosing based on each patient's needs in accordance with the instructions for dosage and administration.

The recent approval came after thorough support for the drug by six clinical studies, including the first and only interventional Phase III study of oral hydrocortisone for Pediatric AI in neonates to children under eight years of age.

"The FDA approval of ALKINDI SPRINKLE is a breakthrough for patients and caregivers treating pediatric adrenocortical insufficiency. We are excited to offer an FDA-approved product that enables low dosing and administration of hydrocortisone to pediatric patients," said Sean Brynjelsen, CEO of Eton Pharmaceuticals. "We look forward to making the product available to patients in the coming months."

For full article click on link: Eton Pharmaceuticals announces FDA approval of orphan drug Alkindi® Sprinkle (hydrocortisone) as replacement therapy in pediatric patients with adrenocortical insufficiency. https://www.globenewswire.com/news-release/2020/09/29/2101010/0/en/Eton-Pharmaceuticals-Announces-FDA-Approval-of-Orphan-Drug-ALKINDI-SPRINKLE-hydrocortisone-as-Replacement-Therapy-in-Pediatric-Patients-with-Adrenocortical-Insufficiency.html

Article Source : Press Release

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr Satabdi Saha

Dr Satabdi Saha (BDS, MDS) is a practicing pediatric dentist with a keen interest in new medical researches and updates. She has completed her BDS from North Bengal Dental College ,Darjeeling. Then she went on to secure an ALL INDIA NEET PG rank and completed her MDS from the first dental college in the country – Dr R. Ahmed Dental College and Hospital. She is currently attached to The Marwari Relief Society Hospital as a consultant along with private practice of 2 years. She has published scientific papers in national and international journals. Her strong passion of sharing knowledge with the medical fraternity has motivated her to be a part of Medical Dialogues.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

FDA approves hydrocortisone oral granules for adrenocortical insufficiency in kids

Similar News

Beyond Scores: Study Enhancing Neonatal Outcomes through APGAR Analysis

PFAS Exposure Linked to Weight Regain After Teen Bariatric Surgery: Study

Children Born Small for Gestational Age Face Higher Risk of Neurodevelopmental Disability by Age 5: Hokkaido Study

Obese Children Face Nearly 5-Fold Higher Risk of Fractures, Study Finds

Pediatric Pain Relief in Laparoscopic Surgery: Study Unravels Anesthetic Dilemma

New guidance to improve safety and outcomes of patent ductus arteriosus closure in premature infants, released by SCAI

Resilience: What protects infants from sudden infant death syndrome?

Strong Leg Muscles Linked to Lower Metabolic Syndrome Risk in Obese Youth: Study